Skip to Main content Skip to Navigation
Journal articles

Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021

Abstract : Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.
Document type :
Journal articles
Complete list of metadata

https://hal.sorbonne-universite.fr/hal-03278110
Contributor : Hal Sorbonne Université Gestionnaire <>
Submitted on : Monday, July 5, 2021 - 12:48:01 PM
Last modification on : Tuesday, July 13, 2021 - 3:28:16 AM

File

eurosurv-26-26-1.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Cécile Tran Kiem, Alessio Andronico, Paolo Bosetti, Juliette Paireau, Lise Alter, et al.. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. Eurosurveillance, European Centre for Disease Prevention and Control, 2021, 26 (26), ⟨10.2807/1560-7917.es.2021.26.26.2100533⟩. ⟨hal-03278110⟩

Share

Metrics

Record views

68

Files downloads

43